Caribou Biosciences Inc

NASDAQ CRBU

Data sourced from iex and EODHD
Download Data

Caribou Biosciences Inc Cash Interest Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2024

Caribou Biosciences Inc Cash Interest Coverage Ratio is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The cash interest coverage ratio measures a company's ability to cover its interest expenses with its operating cash flow. It is calculated by dividing operating cash flow by interest expense. This ratio indicates the company's capacity to generate sufficient cash flow to meet its interest obligations. A higher ratio signifies better coverage and financial stability.
  • Caribou Biosciences Inc Cash Interest Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was -518.42, a 80.42% change year over year.
  • Caribou Biosciences Inc Cash Interest Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was -2,647.63, a -6,025.24% change year over year.
  • Caribou Biosciences Inc Cash Interest Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was -43.23, a 98.60% change year over year.
  • Caribou Biosciences Inc Cash Interest Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was -3,081.00.
NASDAQ: CRBU

Caribou Biosciences Inc

CEO Dr. Rachel E. Haurwitz Ph.D.
IPO Date July 23, 2021
Location United States
Headquarters 2929 7th Street, Berkeley, CA, United States, 94710
Employees 158
Sector Healthcare
Industry Biotechnology
Description

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

StockViz Staff

September 19, 2024

Any question? Send us an email